Supported by Dell Children’s Medical Center, the commitment of the Children’s Blood & Cancer Center (CBCC) to lead the fight against childhood cancer and blood disorders is stronger than ever. We believe research lies at the heart of all medical progress.

Clinical Trial Research

Most children diagnosed with cancer today will survive, thanks to years of medical research driven by the inquisitive minds of scientists and researchers. Much work remains to find treatments and cures for children’s cancer, the leading cause of death by disease in children. Dell Children’s Medical Center is a teaching hospital and a member of the international Children’s Oncology Group (COG), a prestigious research collaborative of approximately 2,000 physician researchers at more than 200 hospitals that is sponsored by the National Cancer Institute. COG is the world’s largest organization devoted exclusively to childhood and adolescent cancer research.

Children’s Blood & Cancer Center patients are offered opportunities to participate in COG studies—the most advanced clinical trials—so each child receives the highest quality of care. Studies show patients treated with COG protocols have significantly better disease-free survival rates than those who don’t receive the same treatments.

CBCC is also a member of the Neuroblastoma and Medulloblastoma Translational Research Consortium, a network of 18 U.S. universities and children’s hospitals. Patients with high-risk neuroblastoma and medulloblastoma cancers are given the chance to participate in clinical trials to improve their quality of life and odds of survival.

All eligible CBCC patients are offered opportunities to participate in clinical trials through Children’s Oncology Group (COG); Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC); Texas-Oklahoma Pediatric Neuro-Oncology Consortium (TOPNOC); and MD Anderson Cancer Center.

Grant Supported Research

CBCC researchers collect clinical patient data through the health experiences of Dell Children’s patients and collaborate with science laboratories throughout local and state academic institutions to study the data. These research projects help us understand why treatments work so that new solutions can be designed to bring better outcomes to patients.

Since Dell Children’s opened in 2007, the CBCC has secured grant funding and has completed or is participating in the following research projects:

  • 2007: Survivor Challenge began as a grant-supported pilot study at the Children’s Blood & Cancer Center that evaluated the effects of organized physical activity on the health and wellbeing of adolescent cancer survivors. Survivor Challenge has become a successful training program for CBCC patients ages 7– 18, who are on or off treatment, and their families.
  • 2012: In collaboration with The University of Texas at Austin, the CBCC began a grant-supported two-year study to investigate the effects of pediatric cancer treatment on the child’s ability to think, learn and behave both during and after cancer treatment. Results of this study could have enormous implications for the prevention and treatment of negative late effects among childhood cancer survivors.
  • 2012: The CBCC began a one-year grant-supported pilot study to evaluate the benefits of a designated neuro-oncology specialty clinic. The program focused on managing care for patients with tumors of the brain and spinal cord, as well as the neurological complications of cancer. By creating a dedicated neuro-oncology program, the CBCC can provide multidisciplinary care in one organized clinic visit so that families are happier, communications are strengthened, and medical care compliance is improved.
  • 2013: In collaboration with the Dell Pediatric Research Institute (a research lab of The University of Texas at Austin), the CBCC began a grant-supported two-year study. Researchers are investigating molecular changes in cancer cell metabolism in response to medications, which could predict outcomes and allow for optimized care and personalized chemotherapy treatments. Results of this bench research will provide the first step toward the development of new strategies for cancer therapy design that could advance international change in pediatric cancer treatment and bring better outcomes to patients.